Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Wolfram Syndrome Type 1
NCT05659368Phase 2Recruiting
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirzepatide in Wolfram syndrome (WFS1), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Changing in endogenous insulin production at 12 months. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
Wolfram syndrome (WFS1)
Beyond the preview
Go deeper on NCT05659368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659368.